SEC Form 4 · accession 0001967326-26-000002
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allyson J Ocean
Director
Period of report
Jun 3, 2026
Accepted (ET)
Jun 5, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 3, 2026 | A | 11,610 | $0.00 | A | 22,934 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $16.15 | Jun 3, 2026 | A | 16,999 | A | Jun 3, 2027 | Jun 3, 2036 | Ordinary Shares | 16,999 | 16,999 | D |
Explanation of responses
- F1Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
- F2Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.